This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Largillier, R. Articles by Milano, G. Search for Related Content PubMed PubMed Citation Articles by Largillier, R. Articles by Milano, G.

Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients

Authors' Affiliations: ¹ Centre Antoine Lacassagne, Nice, France and ² Pharmacokinetic Unit, La Timone University Hospital, Marseille, France

Requests for reprints: Gérard Milano, Oncopharmacology Unit, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France. Phone: 33-4-92-03-15-53; Fax: 33-4-93-81-71-31; E-mail: gerard.milano{at}nice.fnclcc.fr.

Purpose: Germinal gene polymorphisms can explain a part of the interpatient pharmacodynamic variability of anticancer drugs, particularly fluoropyrimidines. Genes for which polymorphisms may potentially influence pharmacodynamics of fluoropyrimidines, including capecitabine, are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and dihydropyrimidine dehydrogenase (DPD).

Experimental design: The aim of this prospective pilot study was to analyze the effect of TS, MTHFR, and DPD gene polymorphisms on toxicity and efficacy in advanced breast cancer patients receiving capecitabine as monotherapy. Germinal polymorphisms of TS (6 bp deletion in the 3' region and 28 bp repeats, including G>C mutation in the 5' region), MTHFR (677C>T and 1298A>C), and DPD (IVS14 + 1G>A) were determined in 105 consecutive patients.

Results: A trend toward a higher global toxicity grade 3 and 4 was observed in patients homozygous for the TS 3RG allele compared with patients heterozygous for the 3RG allele or patients not carrying the 3RG allele (50% versus 19% versus 13% respectively, P = 0.064). The sole patient bearing the DPD IVS14 + 1G>A mutation (heterozygous) deceased from hematologic toxicity. The median response duration was 5.8 months (95% confidence interval, 4.3-7.2). Duration of response was significantly shortened in patients homozygous for the 3RG allele compared with others (P = 0.037).

Conclusions: The present data suggest that 3RG3RG breast cancer patients are not good candidates for capecitabine therapy. In addition, attention should be paid to DPD deficiency in breast cancer patients receiving capecitabine. These preliminary data require further confirmation on a larger number of patients.

This article has been cited by other articles:

				M.-C. Etienne-Grimaldi, J.-L. Formento, M. Francoual, E. Francois, P. Formento, N. Renee, P. Laurent-Puig, M. Chazal, D. Benchimol, J.-R. Delpero, et al. K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy Clin. Cancer Res., August 1, 2008; 14(15): 4830 - 4835. [Abstract] [Full Text] [PDF]

				M.-Y. Huang, Y.-H. Wang, F.-M. Chen, S.-C. Lee, W.-Y. Fang, T.-L. Cheng, M.-F. Hou, J.-Y. Wang, and S.-R. Lin Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC Highly Correlated with Early Relapse of Breast Cancer Patients in Taiwan Ann. Surg. Oncol., March 1, 2008; 15(3): 872 - 880. [Abstract] [Full Text] [PDF]

				R. Sharma, J. M. Hoskins, L. P. Rivory, M. Zucknick, R. London, C. Liddle, and S. J. Clarke Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients Clin. Cancer Res., February 1, 2008; 14(3): 817 - 825. [Abstract] [Full Text] [PDF]

				J. Aisner Overview of the changing paradigm in cancer treatment: Oral chemotherapy Am. J. Health Syst. Pharm., May 1, 2007; 64(9_Supplement_5): S4 - S7. [Abstract] [Full Text] [PDF]